Review of non-surgical treatments for pancreatic neuroendocrine tumors covers somatostatin analogs, PRRT, and emerging therapies with efficacy and safety assessment.
Key findingReview of non-surgical treatments for pancreatic neuroendocrine tumors covers somatostatin analogs,
What the researchers found
Review of non-surgical treatments for pancreatic neuroendocrine tumors covers somatostatin analogs, PRRT, and emerging therapies with efficacy and safety assessment.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Meta-analysis comparing efficacy and safety across somatostatin analogs, PRRT, targeted drugs, chemotherapy, and immunotherapy for pNETs.
How the study worked
Methodology in publication.
Who was studied
Patients with pancreatic neuroendocrine tumors across multiple treatment studies
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Efficacy and Safety of Non-Surgical Treatments for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
Pharmaceuticals (Basel, Switzerland), 18(11)
Citation
AlQahtani, Mohammed Saad; Miutescu, Bogdan; Domilescu, Ielmina; Negru, Serban; Popovici, Dorel; Gadour, Eyad. (2025). Efficacy and Safety of Non-Surgical Treatments for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.. Pharmaceuticals (Basel, Switzerland), 18(11). https://doi.org/10.3390/ph18111650